Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992 low (20mg) dosage
Drug: BIBW 2992 medium (40mg) dosage
Drug: BIBW 2992 high (50mg) dosage
Drug: Vinorelbine i.v. 25 mg/m²
Drug: Vinorelbine per os 60 mg/m²
Drug: Vinorelbine per os 80 mg/m²

First Posted Date: 2009-05-21

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 55

Registration Number: NCT00906698

Locations: 🇫🇷
1200.69.3301 Boehringer Ingelheim Investigational Site, Toulouse Cedex, France
🇫🇷
1200.69.3302 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Phase 1

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 207127 low dose + SOC
Drug: BI 207127 middle dose +SOC
Drug: BI 207127 high dose+SOC
Drug: Placebo + SOC

First Posted Date: 2009-05-20

Last Posted Date: 2016-04-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 75

Registration Number: NCT00905632

Locations: 🇫🇷
1241.7.3307A CHU de Grenoble, Grenoble cédex 9, France
🇫🇷
1241.7.3303A Hôpital Claude Huriez, Lille, France
🇩🇪
1241.7.49011 Boehringer Ingelheim Investigational Site, Freiburg, Germany

and more 15 locations

A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Nevirapine Immediate Release (IR)
Drug: Nevirapine Extended Release (XR)

First Posted Date: 2009-05-20

Last Posted Date: 2016-01-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT00905489

Locations: 🇿🇦
1100.1518.2703 Boehringer Ingelheim Investigational Site, Parow Valley, South Africa
🇺🇸
1100.1518.0001 Boehringer Ingelheim Investigational Site, Washington, District of Columbia, United States
🇺🇸
1100.1518.0002 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 7 locations

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: BIBF 1120
Drug: mFolfox 6
Drug: mFolfox
Drug: bevacizumab

First Posted Date: 2009-05-20

Last Posted Date: 2015-02-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 128

Registration Number: NCT00904839

Locations: 🇫🇷
1199.51.3306C Boehringer Ingelheim Investigational Site, Nice Cedex 2, France
🇫🇷
1199.51.3305A Boehringer Ingelheim Investigational Site, Toulouse cedex 3, France
🇫🇷
1199.51.3308B Boehringer Ingelheim Investigational Site, Saint Herblain, France

and more 44 locations

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

Completed

Conditions: Hypertension
Cardiovascular Diseases

First Posted Date: 2009-05-19

Last Posted Date: 2012-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 211

Registration Number: NCT00904371

Locations: 🇸🇮
Boehringer Ingelheim Investigational Site 23, Golnik, Slovenia
🇸🇮
Boehringer Ingelheim Investigational Site 24, Brezice, Slovenia
🇸🇮
Boehringer Ingelheim Investigational Site 32, Golnik, Slovenia

and more 33 locations

An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Completed

Conditions: Hypertension

First Posted Date: 2009-05-19

Last Posted Date: 2014-04-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1095

Registration Number: NCT00904215

Locations: 🇰🇷
Boehringer ingelheim Investigational Site 4, Daegu, Korea, Republic of
🇰🇷
Boehringer ingelheim Investigational Site 1, Daegu, Korea, Republic of
🇰🇷
Boehringer ingelheim Investigational Site 9, Daejeon, Korea, Republic of

and more 8 locations

Telmisartan Tab Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)

First Posted Date: 2009-04-29

Last Posted Date: 2014-04-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2913

Registration Number: NCT00890084

Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2009-04-23

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1504

Registration Number: NCT00887289

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 1, Zwickau, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 2, Zwickau, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 3, Wuppertal, Germany

and more 31 locations

TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium

Completed

Conditions: Hypertension

First Posted Date: 2009-04-22

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2874

Registration Number: NCT00886288

Locations: 🇧🇪
Boehringer Ingelheim Investigational Site 17, Alleur, Belgium
🇧🇪
Boehringer Ingelheim Investigational Site 22, Amougies, Belgium
🇧🇪
Boehringer Ingelheim Investigational Site 23, Anderlues, Belgium

and more 933 locations

MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment

Completed

Conditions: Prostatic Hyperplasia

First Posted Date: 2009-04-21

Last Posted Date: 2013-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1342

Registration Number: NCT00885027

Locations: 🇨🇴
Boehringer Ingelheim Investigational Site, Villavicencio, Colombia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy